If there was any lingering hope that Vical’s gene therapy might show efficacy in regrowing leg arteries, it has been completely dashed. In trial results that were declared definitive by the lead investigator, Temusi showed itself to be no better than placebo for averting leg amputations and death in patients with critical limb ischaemia (CLI), another blow for a gene therapy space hoping for a big success (AHA Preview – Novel therapies creating excitement at heart conference, November 10, 2010).There was little expectation that the full Tamaris phase III trial data would be more positive than the topline results announced in September (Gene therapy suffers another blow as Temusi crashes out, September 23, 2010). However, in detailing the data at the American Heart Association meeting, lead investigator Dr William Hiatt suggested that gene therapy is unlikely to bear fruit in the angiogenic approach to treating the debilitation condition.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: email@example.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
Terms & Conditions